؉ cells follow the same calcineurin-dependent pattern as in T lymphocytes, suggesting that NFATc2 activation in these cells is equally sensitive to inhibition with CsA. Finally, in vitro proliferation, but not differentiation, of CD34 ؉ cells cultured in the presence of fms-like tyrosine kinase 3 ligand (FLT3L), stem cell factor, granulocyte macrophage-colony stimulating factor (GM-CSF), interleukin-3, and G-CSF is profoundly inhibited by treatment with CsA in a dose-dependent manner. These results suggest a novel and unexpected role for members of the NFAT transcription factor family in the hematopoietic system. J. Leukoc. Biol.
INTRODUCTION
Transcription factors of the nuclear factors of activated T cell (NFAT) family, originally identified in lymphocytes as a nuclear complex binding to the interleukin-2 (IL-2) promoter [1] , are established as one of the key elements of inducible gene expression in activated T cells [2] [3] [4] [5] . NFAT proteins reside in the cytoplasm of resting lymphocytes in an inactive, phosphorylated state. Following T cell receptor ligation, their activation occurs in three consecutive steps: dephosphorylation by the calcium-dependent phosphatase calcineurin, translocation from the cytoplasm into the nucleus, and binding to specific elements of the enhancer regions of their target genes, namely a multitude of cytokines, chemokines, and cell-surface receptors. The clinical relevance of NFAT proteins is suggested by the fact that they are presumed to be the molecular targets of the calcineurin inhibitors cyclosporin A (CsA) and FK506 [2, 6] , mediating their immunosuppressive effects in stem cell and solid organ transplantation. Consistently, infants with an inherited defect of NFAT activation in their lymphocytes suffer from severe combined immunodeficiency [7, 8] .
To date, four calcium-regulated NFAT proteins with partly distinct but overlapping tissue distribution have been identified: NFATc2 (also termed NFAT1), NFATc1 (NFAT2), NFATc4 (NFAT3), and NFATc3 (NFAT4); a fifth family member, NFAT5, is regulated by osmotic stress. NFAT family members share many target genes; however, knockout mice and other models have also revealed unique and unexpected functions of individual proteins [9 -11] . Notably, expression of NFAT proteins is not restricted to T cells but is detectable in a number of other immune as well as nonimmune cells. Whereas in lymphocytes and other cell types, NFAT proteins predominantly regulate the rapid activation of inducible genes of fully differentiated cells, in some tissues, they exert a second biological function, namely the control of tissue differentiation and adaptation [4, 12, 13] . Specifically, NFAT family members are involved in the regulation of chondrocyte [14] , myocyte [15] , adipocyte [16] , keratinocyte [17] , and endothelial cell [18] differentiation, as well as in the development of cardiac valves [19] and vessels [20] and the hypertrophy reaction of skeletal [21] and heart muscle cells [22] . CD34 ϩ cells of bone marrow, cord blood (CB), and granulocyte-colony stimulating factor (G-CSF)-mobilized peripheral blood (PBL) are known to be enriched for hematopoietic stem cells (HSCs) and provide long-term repopulating activity when used as a source for allogeneic stem cell transplantation [23] [24] [25] . A network of extrinsic and intrinsic factors including cytokines, cytokine receptors, and transcription factors [26 -29] controls two fundamental properties of HSCs, self-renewal and differentiation. For example, differentiation of HSCs into the diverse myeloid lineages requires the presence of specific transcription factors such as CCAAT/enhancer-binding protein ␣ (C/EBP␣; for the differentiation of neutrophils), PU-1 (for monocytes/macrophages), and GATA-1 (for erythrocytes, eosinophils, and megakaryocytes). Most of these transcription factors are coexpressed at low levels in early CD34 ϩ CD38 -progenitor cells [30] ; once differentiation of a given myeloid lineage is initiated, the expression of lineage-specific factors is up-regulated, and the expression of others is suppressed. By experimental manipulation of these mechanisms, the route or efficacy of differentiation can be affected [28, 29, 31] . Although regulation and function of NFAT proteins in lymphocytes have been studied extensively, little is known about their expression and potential biological relevance in myeloid cells. Furthermore, no reports exist about whether hematopoietic stem and progenitor cells express NFAT genes or proteins or if they are specifically regulated during myeloid differentiation. In the current study, we analyzed the expression and regulation of NFAT family members in CD34 ϩ cells, as well as in myeloid cells of various lineages and at different stages of maturation. We found that NFATc2 mRNA and protein are expressed at surprisingly high levels in CD34 ϩ cells and are rapidly down-regulated during granulocytic differentiation. Furthermore, the NFAT inhibitor CsA profoundly inhibits proliferation of CD34 ϩ cells but not their differentiation into neutrophil granulocytes.
MATERIALS AND METHODS

Reagents
The following recombinant human (rh) cytokines were used: granulocytemacrophage (GM)-CSF (Novartis Pharma GmbH, Nü rnberg, Germany), G-CSF (Chugai Pharma, Frankfurt, Germany), stem cell factor (SCF; Amgen, Thousand Oaks, CA), fms-like tyrosine kinase 3 ligand (FLT3L), and IL-3 (R&D Systems, Minneapolis, MN). Fluorescein isothiocyanate-and phycoerythrinlabeled monoclonal antibodies (mAb) against human isotypes, CD3, CD19, CD14, CD15, and CD34 were purchased from BD Biosciences (Palo Alto, Ca) and Beckman Coulter Immunotech (Fullerton, CA). The mAb to NFATc2 was obtained from Transduction Laboratories (Lexington, KY), the polyclonal NFATc2 antiserum was a gift from Dr. Anjana Rao (Harvard Medical School, Boston, MA), the mAb against NFATc1 was purchased from Affinity Bioreagents (Golden, CO), and the polyclonal antibody against NFATc3 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell isolation
CD34
ϩ cells and monocytes were purified from the blood of G-CSF-mobilized, healthy stem cell donors; in selected experiments, CD34 ϩ cells were isolated from umbilical CB scheduled for discard. Total bone marrow was obtained by iliac crest aspiration from healthy stem cell donors. Neutrophil granulocytes and mononuclear cells were isolated from the PBL of healthy volunteers. The study was approved by the institutional review board of the medical faculty of the Technical University Dresden (Germany), and informed consent was obtained from the donors.
For CD34
ϩ cell isolation, a sample of the leukapheresis product was centrifuged and resuspended in phosphate-buffered saline (PBS; PAA Laboratories, Pasching, Austria) containing 0.4% acid citrate dextrose (Baxter, Mü nchen-Unterschleissheim, Germany) and 0.5% human serum albumin (Baxter). CD34 ϩ cells and/or CD14 ϩ monocytes were positively isolated by immunomagnetic selection using the CD34 progenitor cell isolation kit and/or CD14 MicroBeads (Miltenyi Biotec GmbH, Bergisch-Gladbach, Germany), following the instructions of the manufacturer. The purities of the resulting CD34 ϩ and CD14 ϩ populations, respectively, were assessed by fluorescenceactivated cell sorting (FACS) and routineously exceeded 95%. Neutrophil granulocytes were isolated by a first-step sedimentation of whole blood on 1.5% dextran T500 (Carl Roth GmbH, Karlsruhe, Germany) followed by centrifugation of the granulocyte-rich supernatant on Ficoll-Hypaque (density 1.077 g/ml; Biochrom AG, Berlin, Germany). The resulting CD15 ϩ population of neutrophil granulocytes was subjected to hypotonic lysis, washed, and resuspended in PBS containing 1% fetal calf serum (FCS; Invitrogen GmbH, Karlsruhe, Germany). Purity was analyzed by FACS using mAb to CD15, CD14, CD3, and CD19 and routineously exceeded 95%. Peripheral blood mononuclear cells (PBMC) and total bone marrow cells were isolated by density gradient centrifugation using Ficoll-Hypaque (1.077 g/ml).
Culture and ex vivo stimulation of CD34
ϩ cells
For short-term ex vivo stimulation, CD34 ϩ cells and PBMC were seeded at 1 ϫ 10 6 /ml in RPMI 1640 (Invitrogen GmbH), supplemented with 2 mM CaCl 2 (Sigma, Deisenhofen, Germany), 10% FCS, 1% penicillin/streptomycin, 10 mM Hepes (PAA Laboratories), and 50 M 2-mercaptoethanol (Merck, Darmstadt, Germany), and stimulated for 30 min at 37°C with the calcium ionophore ionomycin (1 M, Calbiochem, Merck Biosciences, Bad Soden, Germany). Where indicated, stimulation was done in the presence of CsA (1 M, Sigma), which was added 30 min prior to ionomycin. At the end of the stimulation, the cells were harvested and directly used for cytospin preparations or protein isolation (see below).
For differentiation experiments, freshly isolated CD34 ϩ cells were seeded at 1 ϫ 10 5 /ml in Cellgro medium (CellGenix, Freiburg, Germany) and cultured for 14 days in the presence of a cytokine cocktail containing rhSCF (50 ng/ml), FLT3L (100 ng/ml), IL-3 (5 ng/ml), GM-CSF (5 ng/ml), and G-CSF (30 ng/ml; days 1-5). On days 5, 8, 11, and 14, cells were harvested, washed, counted, and expanded with fresh media supplemented with cytokines (day 5: IL-3 and G-CSF; day 8 and 11: G-CSF) or used directly for further analysis (see below). Where indicated, CsA was added to the cultures.
Morphologic analysis and flow cytometry
The morphology of the cells was analyzed by staining cytospin preparations with May-Grü nwald-Giemsa. The phenotype and/or differentiation efficacy was analyzed by FACS.
Immunofluorescence of cytospins
After ex vivo stimulation, cytospin preparations were fixed in 3% neutrally buffered paraformaldehyde, washed, blocked with PBS/10% FCS, and permeabilized with 0.5% Nonidet P-40 (NP-40; Boehringer Mannheim, Mannheim, Germany). The cells were then incubated for 30 min with the mAb against NFATc2, diluted 1:1000 in blocking buffer (PBS, 10% FCS, 0.5% NP-40), washed, and incubated for 30 min with the secondary antibody (Cy3-labeled sheep anti-mouse immunoglobulin G, Sigma), diluted 1:1000 in blocking buffer. Slides were mounted using the SlowFade antifade kit (Molecular Probes, Eugene, OR) containing 4Ј,6-diamidine-2Ј-phenylindole dihydrochloride, analyzed with a Nikon Labophot-2 fluorescence microscope and processed by ISISF software (MetaSystems GmbH, Altlussheim, Germany).
Immunohistochemistry and immunofluorescence of bone marrow biopsies
Bone marrow biopsies from routine pathology cases were fixed in 4% neutrally buffered formaldehyde for 24 h, decalcified with 270 mM EDTA (pH 7.4) for 12 h, and embedded in paraffin. For all immunolabelings, antigen recovery was performed by microwave pretreatment. For immunohistochemistry, the mAb to NFATc2 was used at a dilution of 1:100. Peroxidase-based detection of the antibody was performed with the LSAB2 horseradish peroxidase (HRP) kit (Dako, Hamburg, Germany), according to the manufacturer's instructions. For immunofluorescence, the mAb to NFATc2 was used at a dilution of 1:50; the polyclonal antiserum to NFATc2 was used at a dilution of 1:5. The mAb to CD34 (Dako) was used at a dilution of 1:50, and the mAb to glycophorin A (Dako) was used at a dilution of 1:500. The secondary antibodies (dichlorotriazinylaminofluorescein-labeled anti-mouse and anti-rabbit; Texas red-labeled anti-mouse and anti-rabbit) were used at a dilution of 1:80. Immunofluorescence pictures were taken at a Zeiss fluorescence microscope equipped with FluoroArc fluorescence control and Optimas 6.5 software.
Western blot analysis
Cells (5-10ϫ10 6 ) were washed with ice-cold PBS, resuspended with Totex buffer (100 l/ 5ϫ10 6 cells) containing 20 mM Hepes buffer (PAA Laboratories), 1% NP-40, 0.42 M NaCl, 20% glycerol, 1 mM MgCl 2 , 10 mM EDTA, 10 g/ml leupeptin, and 0.5 M dithiothreitol (DTT; Sigma), and freshly supplemented with 1 mM phenylmethylsulfonyl fluoride and 20 mM sodium pyrophosphate (Sigma) and vortexed for 20 min at 4°C. Protein was quantified in duplicate with the bicinchoninic acid kit (Pierce, Rockford, IL) using bovine serum albumin as standard.
From each sample, 30 g total protein was separated by 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; BioRad, Hercules, CA) and transferred to a nitrocellulose membrane [0. For nonquantitative analysis of NFATc1-4, PCR was performed in a 50-l vol containing 1 l cDNA, 2.5 IU AmpliTaq Gold polymerase (Applied Biosystems, Foster City, CA), 200 M dNTPs (Invitrogen), GeneAmp 10ϫ PCR buffer (Applied Biosystems), 1.5 mM MgCl 2 , and 300 nM primers. The following primers were used: NFATc2 forward, 5Ј-AGAAACTCGGCTCCAGAATCC-3Ј; NFATc2 reverse, 5Ј-TGGTTGCCCTCATGTTGTTTTT-3Ј; NFATc1 forward, 5Ј-GCCGCAGCACCCCTACCAGT-3Ј; NFATc1 reverse, 5Ј-TTCTTCCTC-CCGATGTCCGTCTCT-3Ј; NFATc4 forward, 5Ј-TCAGAAGACACGGCG-GACTTCC-3Ј; NFATc4 reverse, 5Ј-TGAACATCTGTAGGGTCAGTGG-3Ј; NFATc3 forward, 5Ј-ACCAGCC-CGGGAGACTTCAATAGA-3Ј; NFATc3 reverse, 5Ј-AAATACCTGCACAATCAATACTGG-3Ј. The PCR conditions were as follows: one cycle at 94°C for 10 min, followed by 30 cycles at 94°C for 30 s, 60°C (NFATc2, NFATc3, and NFATc4) or 64°C (NFATc1) for 30 s, 72°C for 30 s, and a final extension cycle at 72°C for 10 min. For the control of RNA and cDNA preparations, we used RT-PCR for ␤-actin. Amplified products were analyzed electrophoretically on a 2% agarose gel and were visualized under ultraviolet rays after ethidium bromide staining.
Real-time RT-PCR was performed on an ABI-Prism 7700 PCR SDS (Applied Biosystems). Validated 6-FAM-labeled PCR primers and Taqman probes for NFATc2 (assay ID: Hs00234855_m1) were used, and VIC-labeled glyceraldehyde 3-phosphate dehydrogenase (GAPDH; ID: 4310884E) served as an endogenous control. PCR mix was prepared according to the manufacturer's instructions (assay-on-demand, Applied Biosystems). PCR was always performed in duplicates. Thermal cycler conditions were as follows: 2 min 50°C, 10 min 95°C, 40 cycles denaturation (15 s, 95°C), and combined annealing/ extension (1 min, 60°C). For the quantification of NFATc2 mRNA expression in differentiating CD34 ϩ cells, mRNA/cDNA levels of NFATc2, after normalization against the housekeeping gene GAPDH, were expressed relative to the value obtained at day 0, calculated by the formula 1/2
x-y (x: threshold cycle [CT] of each sample; y: Ct at day 0). For the quantification of NFATc2 mRNA expression in different cell types, PCR fragments of NFATc2 (amplified with the above TaqMan primers) were cloned into the pCR 2.1-TOPO vector (Invitrogen) and quantified, and copy numbers were calculated based on the molecular weight. NFATc2 mRNA copy numbers of each sample were then determined by plotting the Ct of each well against a reference curve prepared by amplifying serial dilutions of the corresponding plasmid. As populations of CD34 ϩ cells, neutrophil granulocytes, monocytes, and Jurkat cells considerably differ in RNA content and GAPDH expression, the respective copy numbers were expressed per g of total cellular RNA.
RESULTS
Expression of NFAT family members in CD34
To determine whether NFAT family members were present in hematopoietic progenitor cells, we assessed the expression of ϩ and T cells [32] . (B) The three bands (middle panel) correspond to the three known isoforms of NFATc1 [33] .
NFAT [26] . CD34 ϩ cells were isolated from the PBL of G-CSF-mobilized stem cell donors to a purity of Ͼ95%, and total cellular RNA and protein were extracted. As shown in Figure 1A , CD34 ϩ cells contained transcripts encoding the NFAT family members NFATc2, NFATc1, and NFATc3 but not NFATc4. On the protein level, CD34
ϩ displayed expression of NFATc2 and at apparently lower levels, NFATc1 and NFATc3 (Fig. 1B) . To estimate the amount of NFAT proteins in CD34 ϩ cells, we compared them to Jurkat cells, a T cell line known to express high levels of NFATc2 [34] . Strikingly, expression levels of NFATc2 (and NFATc1) in CD34 ϩ and Jurkat cells were comparable, whereas levels of NFATc3 were considerably lower in CD34 ϩ cells than in Jurkat cells (Fig. 1C  and data not shown) . To exclude that expression levels of NFATc2 in CD34 ϩ cells were affected by the source of stem cell isolation or by G-CSF treatment of the stem cell donors, we also analyzed NFATc2 expression in CD34 ϩ cells purified from umbilical CB. CD34
ϩ cells of CB, as compared with bone marrow and PBL, are presumed to contain the highest percentage of primitive precursor cells [35, 36] . As shown in Figure  1D , CD34 ϩ cells isolated from G-CSF-mobilized PBL and CB displayed similar levels of NFATc2 protein, indicating that high-level NFATc2 expression by CD34 ϩ hematopoietic progenitor cells is a cell-intrinsic, G-CSF-independent phenomenon. Finally, some degree of interindividual variability between stem cell donors was observed: Whereas expression of NFATc2 protein in most CD34
ϩ cell preparations was uniformously high, those of a small group of donors (three out of 16 preparations tested) displayed comparably low levels of the protein (data not shown).
NFATc2 is expressed in CD34 ϩ cells and megakaryocytes but not in cells of other myeloid lineages
We then asked whether NFATc2 was detectable at later stages of myeloid development. Total cellular RNA and protein were prepared from unseparated bone marrow as well as from purified PBL neutrophil granulocytes and monocytes, isolated from healthy volunteers to a purity of Ͼ95%. In striking contrast to CD34 ϩ cells, expression of NFATc2 protein was neither detectable in mature granulocytes or monocytes nor in extracts of total bone marrow, which predominantly (ϳ60%) consists of immature myeloid precursor cells at various stages of differentiation ( Fig. 2A) . This suggested that expression of NFATc2 in CD34 ϩ progenitor cells is lost in differentiating and mature myeloid cells of the neutrophilic/monocytic lineages.
We extended this observation in two ways. First, we determined, by quantitative RT-PCR, the expression profile of NFATc2 in CD34 ϩ cells, in PBL neutrophil granulocytes, and in PBL monocytes on the RNA level (Fig. 2B ). In line with the above results with NFATc2 protein, NFATc2 transcript levels in neutrophil granulocytes were about fourfold lower than in CD34 ϩ cells, and in monocytes were almost undetectable. Second, we performed immunohistochemistry and immunofluorescence on sections of normal human bone marrow biopsies to analyze NFATc2 expression in myeloid lineages other than neutrophils and monocytes. Consistent with the above results, NFATc2 staining colocalized with the expression of CD34 (Fig. 3A) but was barely detectable in neutrophil granulocytes (arrows in Fig. 3B ). Unexpectedly, NFATc2 was found to be strongly expressed by megakaryocytes (arrowhead in Fig. 3B ). In contrast, it could not or only weakly be detected in glycophorin A ϩ erythroid cells (Fig. 3C) ; however, it has to be noted that low-level expression beyond the sensitivity limit of the polyclonal antiserum used in Figure 3 , A and C, cannot be excluded. In summary, NFATc2 mRNA and protein are expressed by CD34 ϩ cells at levels comparable with those found in T lymphocytes. Furthermore, NFATc2 protein is also readily detectable in megakaryocytes but not in differentiating or mature cells of the neutrophilic, monocytic, and erythroid lineages.
Down-regulation of NFATc2 expression during myeloid differentiation
Our observation that NFATc2 is expressed in CD34 ϩ stem and early progenitor cells but not in cells further maturated along the myelomonocytic lineage suggests that in the course of myelomonocytic differentiation, the expression of NFATc2 is suppressed. To test this hypothesis, we cultured CD34 ϩ cells in the presence of a sequential cytokine cocktail known to induce their differentiation into neutrophil granulocytes [37, 38] . Morphological evaluation of cytospin preparations (data not shown) and assessment of CD34 and CD15 expression by FACS (Fig. 4A) indicated that differentiation was efficient and occurred within a period of ϳ2 weeks; furthermore, it was accompanied by considerable proliferation of the cells (Fig.  4B) . Strikingly, as early as 5 days after the start of differentiation, the expression of NFATc2 protein (Fig. 4C) and mRNA  (Fig. 4D) in the differentiating cells was almost completely suppressed. The time-point of down-regulation of NFATc2 correlated with the development of a promyelocytic phenotype (data not shown) and the loss of CD34 expression (Fig. 4A) . Thus, expression of NFATc2 in CD34 ϩ cells is rapidly suppressed upon progression of the cells into the promyelocytic stage, consistent with the observed expression profile of NFATc2 in immature and mature myeloid cells isolated from bone marrow and PBL.
CsA inhibits cytokine-induced proliferation but not differentiation of CD34 ϩ cells
Two fundamental properties of hematopoietic stem cells, selfrenewal and differentiation, are controlled by the coordinated expression of transcription factors such as HOXB4 [39] , C/EBP␣ [40] , and PU-1 [41] , but the function of NFATc2 in CD34 ϩ cells is unknown. In T lymphocytes and most other cell types tested, NFATc2 is target for the calcineurin inhibitor CsA, which completely abrogates NFAT-mediated gene expression and therefore has been useful as a tool to evaluate NFAT functions in these cells [2, 6] . Before we could similarly test the effect of CsA on CD34 ϩ cells, we had to establish whether NFATc2 regulation in these cells follows the same calcium-dependent/CsA-sensitive pattern as in T cells. As shown in Figure 5A , a 30-min treatment of CD34 ϩ cells with the calcium ionophore ionomycin resulted in increased migration of the NFATc2 band in SDS-PAGE/Western blot, which in earlier studies using T cells had been demonstrated to correspond to dephosphorylation of the protein [42] . Similarly, ionomycin treatment induced complete translocation of NFATc2 from the cytoplasm into the nucleus of the cells (Fig. 5B) . Ionomycin-induced dephosphorylation and nuclear translocation of NFATc2 were completely blocked by the addition of CsA (Fig. 5, A and B) . Therefore, NFATc2 regulation in CD34 ϩ cells is dependent on calcium/calcineurin activation and sensitive to inhibition by CsA.
We then determined the effect of CsA on CD34 ϩ cell proliferation and differentiation. CD34 ϩ cells were purified from the PBL of G-CSF-mobilized donors and cultured in vitro with the same sequential cytokine cocktail used in Figure 4 in the presence or absence of increasing amounts of CsA. As shown in Figure 6A , CsA profoundly inhibited the proliferation of CD34 ϩ cells in a dose-dependent manner. Notably, the effect of CsA on proliferation of the cells was most prominent in the first 5 days of the culture (Fig. 6A, inset) , the time-frame in which the differentiating cells still express high levels of NFATc2 (Fig. 4, C and D) . The inhibitory effect of CsA on the proliferatve response of CD34 ϩ cells was not restricted to a particular cytokine or cytokine combination but rather appeared to reflect suppression of a more general downstream proliferative mechanism of CD34 ϩ cells (Fig. 6B) . As opposed to its effect on proliferation, the presence of CsA did not inhibit the differentiation of the cells monitored by the acquisition of a typical morphology (data not shown) and surface expression of the neutrophil marker CD15 (Fig. 6C) . In contrast, in the CsA-treated cultures, even a slight (yet nonsignificant) trend toward an increased differentiation efficacy was noticeable. These results suggest that CsA inhibits the cytokine-induced proliferation of CD34 ϩ cells at already low and clinically relevant doses of the drug, whereas its effect on neutrophilic differentiation (if any) is rather permissive than inhibitory.
DISCUSSION
Whereas expression, regulation, and function of NFAT in lymphoid cells have been studied extensively, little is known about the role of NFAT in myeloid cells. In the current study, we analyzed expression and regulation of NFAT in CD34 ϩ cells as well as in differentiating and mature cells of diverse myeloid lineages. We found considerable expression of NFATc2 in CD34 ϩ cells and megakaryocytes but not in cells of the neutrophilic, monocytic, or erythroid lineages. Together with recent reports describing the expression of NFATc2 in human eosinophils [43, 44] and murine mast cells [45, 46] , our results delineate a differential expression pattern of NFATc2 in cells of diverse myeloid lineages. As all myeloid cells originate from a common, immature precursor, we postulate that the expression of NFATc2 during the development of myeloid cells follows a distinct and lineage-specific pattern in which it is suppressed in CD34 ϩ cells differentiating toward the neutrophilic, monocytic, or erythroid lineages, whereas it is maintained in cells differentiating into eosinophil granulocytes, mast cells, or platelets. We confirmed this theory in part by showing that the expression of NFATc2 mRNA and protein is profoundly suppressed in CD34 ϩ cells forced to differentiate into neutrophil granulocytes in vitro. Further experiments will establish the exact expression pattern of NFAT family members in CD34 ϩ cells differentiating into the various myeloid lineages; this information will be important to estimate and further evaluate the potential role of NFAT in the control of lineage-specific decisions. CD34 ϩ cells are known to coexpress several transcription factors at low levels, and specific combinations of transcription factors determine the survival, proliferation, and differentiation responses of CD34 ϩ cells to extrinsic or intrinsic signals [29, 30, 47] . The observation that NFATc2 is expressed in CD34 ϩ cells is novel and may indicate unexpected functions for this transcription factor family in the hematopoietic system. Expression levels for NFATc2 mRNA and protein in CD34 ϩ cells were surprisingly high and comparable with those found in Jurkat cells, a T cell line that contains considerable amounts of NFATc2 [34] . As we used CD34 ϩ cells of G-CSF-mobilized PBL in most of our experiments, we considered it important to confirm NFATc2 expression in CD34 ϩ cells of bone marrow (Fig. 3A) and CB (Fig. 1D) . CD34 ϩ cells isolated from these sources differ in their frequency of primitive precursor cells [48] , proliferative potential [49] , and cell-cycle status [35] . The results show that CD34 ϩ cell expression of NFATc2 is independent of the source and furthermore in PBL not notably influenced by potentially confounding effects of the mobilizing [42] . (B) Calcineurin-dependent nuclear translocation of NFATc2. Cytospin preparations of CD34 ϩ cells were prepared, and the subcellular localization of NFATc2 was visualized by immunofluorescence using a mAb to NFATc2. PBMC were used as a control.
cytokine G-CSF. An interesting, yet open, point is the question of whether NFATc2 is differentially expressed in subgroups of the CD34 ϩ population, especially if it can be detected in primitive hematopoietic precursor cells (e.g., CD34
ϩ CD38 -). Another important aspect was to work out the mechanisms by which NFATc2 is regulated in CD34 ϩ cells. In most cell types, NFAT activation occurs via the "classical" Ca 2ϩ /calcineurin-dependent, CsA-sensitive pathway of dephosphorylation and nuclear translocation; however, calcineurin-/CsA-independent pathways also exist [50 -52] . Furthermore, to our knowledge, the presence of calcineurin (phosphatase 2B) in CD34 ϩ cells has not yet been reported. Our results indicate that as in T lymphocytes, NFATc2 in CD34 ϩ cells is constitutively cytoplasmic and responds alike to pharmacological stimulation and inhibition of calcineurin. The physiological stimulus for NFATc2 activation in CD34 ϩ cells remains presently unclear; the most likely candidates are cytokines and growth factors, which in other cell types are known to be capable of increasing intracellular calcium levels sufficient for calcineurin activation [53, 54] . Exemplary for the hematopoietic system are eosinophils, in which stimulation with IL-4 and IL-5 has recently been demonstrated to result in NFAT activation [43] .
The predominant task of future studies will be to define the biological role of NFATc2 in CD34 ϩ cells. As a first step, we approached this question indirectly by assessing the effect of CsA on CD34 ϩ cells in vitro, taking advantage of our observation that the activation of NFATc2 in CD34 ϩ cells was sensitive to this drug. We therefore postulated that any effect of NFATc2 on CD34 ϩ cell self-renewal/proliferation, apoptosis/ death, or differentiation/commitment would be neutralized by the presence of CsA; conversely, CD34 ϩ cell functions found to be resistant to CsA would unlikely be mediated by NFATc2. CsA profoundly suppressed the proliferative response of CD34 ϩ cells to a cocktail of hematopoietic growth factors in liquid culture in a dose-dependent manner (Fig. 6A) . Inhibition of CD34 ϩ cell proliferation was evident at even low and clinically relevant levels of CsA. Few reports exist in the literature addressing the effect of CsA on the proliferation and/or differentiation of hematopoietic precursor cells, most of which are hampered by the problem that as a result of the presence of lymphocytes in the cellular culture, direct and indirect effects of CsA on CD34 ϩ cells could not be adequately separated [55, 56] . In one study by Perry et al. [57] , an antiproliferative effect of CsA was reported on the colony growth of highly enriched, murine hematopoietic precursor cells (Thy-1.1 low Sca1 ϩ Lin -) stimulated in methylcellulose cultures with SCF, IL-3, IL-6, G-CSF, and erythropoietin. At first sight, the antiproliferative effect of CsA on CD34 ϩ cells in vitro may be surprising, as CsA is commonly used in patients after allogeneic stem cell transplantation, and in this situation does not appear to affect the normal hematopoietic recovery of the patients after the conditioning therapy. However, we also show that CsA does not suppress (and even may facilitate) the differentiation of myeloid precursor cells; furthermore, the antiproliferative effect of CsA at concentrations achieved in vivo (ϳ200 ng/ml) is relatively weak (Fig. 6A) and probably outweighed by suppression of T cell-derived interferon-␥, which is known to inhibit the colony formation of hematopoietic stem cells [58, 59] . Nevertheless, the negative effect of CsA on the proliferation of CD34 ϩ cells characterizes this drug as less than optimal for the immunosuppressive treatment of patients after allogeneic stem cell transplantation, and the search for agents acting more specifically on lymphocytes appears to be desirable for this patient group.
